Skip to main navigation Skip to search Skip to main content

Reversing cachexia

  • Michael J. Tisdale*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

Original languageEnglish
Pages (from-to)511-512
Number of pages2
JournalCell
Volume142
Issue number4
DOIs
Publication statusPublished - 20 Aug 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Reversing cachexia'. Together they form a unique fingerprint.

Cite this